WebJul 22, 2024 · Pharmacokinetics not affected by mild (Cl cr 50–80 mL/minute), moderate (Cl cr 30 to <50 mL/minute), or severe (Cl cr <30 mL/minute) renal impairment. Pharmacokinetics have not been evaluated in patients with renal impairment requiring dialysis. Common Adverse Effects WebAug 22, 2024 · Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery (designated an orphan drug by FDA for this indication). Non-small Cell Lung Cancer
Effects of 5‐HT₃ receptor antagonists on cisplatin‐induced …
WebSep 21, 2016 · The pharmacokinetics and pharmacodynamics of docetaxel and cisplatin were compared in elderly and non-elderly patients. Results There were no differences in pharmacokinetics of docetaxel or cisplatin between elderly versus non-elderly patients with regard to clearance and volume of distribution. WebJan 25, 2008 · For the cisplatin pharmacokinetic studies, the measured absorbance values for the 10 mice receiving cisplatin only were described with a one-compartment pharmacokinetic model. The measured absorbance values at 6 h for the two mice that received STS together with cisplatin were compared with the prediction for the model. … fisher price printable coupons
Population pharmacokinetics of total and unbound …
WebDec 1, 1992 · The pharmacokinetic profile of vinorelbine is often described as a 3-compartment model characterised by a long terminal half-life that varies between 20 and 40 hours and a large apparent volume of distribution (Vd) of around 70 L/kg. 86 Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer D. Levêque, E. Quoix, WebCisplatin was administered to seven patients with advanced cancer in divided doses of 40 mg/m2 body surface daily for 5 consecutive days. The pharmacokinetics of total Pt was studied on the days 1, 3 and 5 of infusion. The renal function was assessed through the parameters usually applied in the cli … WebJan 16, 2016 · Purpose A phase I study combining daily oral pazopanib and cisplatin (given iv every 3 weeks) was performed in order to determine the maximum tolerated dose of both drugs in combination. Pharmacokinetic interactions were evaluated. Methods Plasma pazopanib and ultrafilterable cisplatin concentrations were obtained in 32 patients … fisher price product testing